885
Participants
Start Date
May 11, 2023
Primary Completion Date
March 18, 2024
Study Completion Date
March 18, 2024
RSVpreF
120-µg
Placebo
Placebo
NYU Langone Health, New York
Columbia University Irving Medical Center, New York
Rochester Clinical Research, LLC, Rochester
GW Medical Faculty Associates, Washington D.C.
GW Vaccine Research Unit, Washington D.C.
Jadestone Clinical Research, Silver Spring
Institute of Human Virology (IHV), Baltimore
Charlottesville Medical Research, Charlottesville
Alliance for Multispecialty Research, LLC, Norfolk
Accellacare - Wilmington, Wilmington
Clinical Neuroscience Solutions - Orlando - South Delaney Avenue, Orlando
Alliance for Multispecialty Research, LLC, Coral Gables
Proactive Clinical Research,LLC, Fort Lauderdale
Central Research Associates, Birmingham
North Alabama Research Center, Athens
Medical Affiliated Research Center, Huntsville
Alliance for Multispecialty Research, LLC, Knoxville
University Hospitals Cleveland Medical Center, Cleveland
University of Iowa, Iowa City
Bozeman Health Deaconess Hospital, Bozeman
Bio-Kinetic Clinical Applications, LLC dba QPS-MO, Springfield
Bio-Kinetic Clinical Applications LLC dba QPS-MO (Patient Screening Only), Springfield
Alliance for Multispecialty Research, LLC, Wichita
University of Nebraska Medical Center, Omaha
University Of Nebraska Medical Center, Omaha
AIM Trials, LLC, Plano
Epic Medical Research, Red Oak
Clinical Trials of Texas, LLC, San Antonio
Orion Clinical Research, Austin
Hope Research Institute, Phoenix
The Pain Center of Arizona, Phoenix
Hope Research Institute, Tempe
Kaiser Permanente, Los Angeles
Orange County Research Center, Lake Forest
Diablo Clinical Research, Inc., Walnut Creek
New England Research Associates, LLC, Bridgeport
Lead Sponsor
Pfizer
INDUSTRY